CBAY CymaBay Therapeutics Inc

Price (delayed)

$2.82

Market cap

$238.79M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.34

Enterprise value

$244.02M

CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need. CymaBay is developing seladelpar, a potent, selective, ...

Highlights
The quick ratio has increased by 32% since the previous quarter but it has declined by 15% year-on-year
CymaBay Therapeutics's net income has plunged by 81% YoY and by 11% from the previous quarter
CymaBay Therapeutics's EPS has plunged by 65% YoY and by 6% from the previous quarter

Key stats

What are the main financial stats of CBAY
Market
Shares outstanding
84.68M
Market cap
$238.79M
Enterprise value
$244.02M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.22
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$94.27M
EBITDA
-$93.58M
Free cash flow
-$74.23M
Per share
EPS
-$1.34
Free cash flow per share
-$0.85
Book value per share
$1.27
Revenue per share
$0
TBVPS
$2.29
Balance sheet
Total assets
$200.64M
Total liabilities
$93.26M
Debt
$79.22M
Equity
$107.38M
Working capital
$178.01M
Liquidity
Debt to equity
0.74
Current ratio
13.68
Quick ratio
13.43
Net debt/EBITDA
-0.06
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-62.4%
Return on equity
-92.3%
Return on invested capital
-85%
Return on capital employed
-50.5%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CBAY stock price

How has the CymaBay Therapeutics stock price performed over time
Intraday
8.88%
1 week
43.15%
1 month
47.64%
1 year
-38.7%
YTD
-16.57%
QTD
-9.32%

Financial performance

How have CymaBay Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$94.47M
Net income
-$100.22M
Gross margin
N/A
Net margin
N/A
CymaBay Therapeutics's net income has plunged by 81% YoY and by 11% from the previous quarter
CymaBay Therapeutics's operating income has plunged by 68% YoY and by 8% from the previous quarter

Growth

What is CymaBay Therapeutics's growth rate over time

Valuation

What is CymaBay Therapeutics stock price valuation
P/E
N/A
P/B
2.22
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
CymaBay Therapeutics's EPS has plunged by 65% YoY and by 6% from the previous quarter
The P/B is 65% lower than the 5-year quarterly average of 6.4 and 11% lower than the last 4 quarters average of 2.5
CBAY's equity is down by 19% QoQ and by 16% YoY

Efficiency

How efficient is CymaBay Therapeutics business performance
CBAY's ROE has shrunk by 147% YoY and by 17% QoQ
CBAY's ROA has shrunk by 79% YoY
CBAY's ROIC is down by 49% YoY but it is up by 18% QoQ

Dividends

What is CBAY's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CBAY.

Financial health

How did CymaBay Therapeutics financials performed over time
CBAY's total assets is 115% more than its total liabilities
CBAY's total assets is up by 47% YoY
CBAY's total liabilities is up by 34% since the previous quarter
CymaBay Therapeutics's debt is 26% less than its equity
CBAY's debt to equity has soared by 95% from the previous quarter
CymaBay Therapeutics's debt has soared by 55% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.